ABIVAX Société Anonyme (NASDAQ:ABVX) Receives Average Rating of “Buy” from Brokerages

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have been given a consensus rating of “Buy” by the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $38.67.

A number of brokerages have weighed in on ABVX. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a report on Friday, January 10th.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Large investors have recently modified their holdings of the company. abrdn plc raised its holdings in shares of ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after purchasing an additional 198,225 shares during the last quarter. BNP Paribas Financial Markets grew its stake in ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the period. Walleye Capital LLC increased its position in shares of ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after purchasing an additional 80,807 shares during the last quarter. Point72 Asset Management L.P. raised its position in ABIVAX Société Anonyme by 28.2% in the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after acquiring an additional 119,300 shares during the period. Finally, GAMMA Investing LLC bought a new position in shares of ABIVAX Société Anonyme during the 4th quarter valued at approximately $29,000. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Stock Performance

Shares of NASDAQ:ABVX opened at $7.40 on Monday. The firm has a 50 day moving average of $6.87 and a 200-day moving average of $9.28. ABIVAX Société Anonyme has a 12 month low of $5.49 and a 12 month high of $17.02.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.